Équilibre is a biopharmaceutical company tackling some of the greatest unmet needs for patients by developing differentiated and novel therapeutic candidates.
We recognize our success is a product of the numerous contributions of our executive officers, scientific, financial, legal, technical personnel and consultants. As we continue to implement our growth strategy, as well as acquire and develop technologies, we will continue to rely on their expertise and dedication.
Our vision is to significantly change the lives of patients by developing medicines that provide truly meaningful improvements in the quality of life and survival of people with neurodegenerative diseases.
Advance Leading Science
We develop transformative medicines faster by building technologies and developing talent in creative ways.
We aim to significantly change the practice of treating neurodegenerative diseases by developing medicines that provide for meaningful improvements in the survival and the quality of lives of patients.
As a data-driven organization, our people are empowered to collaboratively make informed, objective decisions quickly across multiple programs.
Équilibre is founded upon advancing science to benefit patients. We are committed to delivering innovative treatments to millions of patients who experience conditions for which there is inadequate or nonexistent treatments. We aim to apply groundbreaking science and transform scientific possibilities into medical opportunities.